D842V

/D842V

Blueprint Medicines Presents Preclinical Data on BLU-285

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]

By |2019-04-08T10:13:47-04:00April 24th, 2015|D842V, News, Research|

D842V Gets Its Moment in the Spotlight

The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.

By |2018-06-12T11:11:01-04:00February 1st, 2011|D842V, News, Patient Registry|

New Treatments of D842V Mutations

 UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]

By |2019-04-03T12:02:19-04:00January 6th, 2011|Clinical Trials, D842V, Diagnosis, Mutational Testing, Mutations, News, Research|

References – PDGFRA and D842V

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin [...]

By |2014-09-03T13:23:03-04:00December 20th, 2007|D842V, Mutations, Research|

KIT and PDGFRA Mutations in GIST: A to Z

This is part one of a two-part series on “KIT and PDGFRA kinase mutations in GIST: from A to Z”. In this newsletter, Dr. Heinrich will provide a background on the role of kinase mutations in GIST, focusing largely on the biological and clinical implications of these mutations. In part two (which will be featured in the July 2007 edition of the newsletter, following the special “Five-year anniversary” edition),

Recent Posts

Upcoming Events

  1. SPAEN hosts webcast by Dr. Trent

    Novel Treatments in GIST

    July 24 @ 2:00 PM
  2. LRG Webcast Series: When to Consider Surgery

    August 8 @ 2:00 PM - 3:00 PM
  3. GDOL Ottawa logo

    GIST Day of Learning – Ottawa

    September 28 @ 9:00 AM - 4:30 PM